Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report

Diane K. Wherrett; Jane L. Chiang; Alan M. Delamater; Linda A. Dimeglio; Stephen E. Gitelman; Peter A. Gottlieb; Kevan C. Herold; Daniel J. Lovell; Trevor J. Orchard; Christopher M. Ryan; Desmond A. Schatz; David S. Wendler; Carla J. Greenbaum

doi:10.2337/dc15-1429

Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report

Diane K. Wherrett, Jane L. Chiang, Alan M. Delamater, Linda A. Dimeglio, Stephen E. Gitelman, Peter A. Gottlieb, Kevan C. Herold, Daniel J. Lovell, Trevor J. Orchard, Christopher M. Ryan, Desmond A. Schatz, David S. Wendler, Carla J. Greenbaum

Pediatrics

Research output: Contribution to journal › Article

38 Scopus citations

Abstract

Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.

Original language	English (US)
Pages (from-to)	1975-1985
Number of pages	11
Journal	Diabetes care
Volume	38
Issue number	10
DOIs	https://doi.org/10.2337/dc15-1429
State	Published - Oct 2015

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialized Nursing

Access to Document

10.2337/dc15-1429

Fingerprint Dive into the research topics of 'Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report'. Together they form a unique fingerprint.

Cite this

Wherrett, D. K., Chiang, J. L., Delamater, A. M., Dimeglio, L. A., Gitelman, S. E., Gottlieb, P. A., Herold, K. C., Lovell, D. J., Orchard, T. J., Ryan, C. M., Schatz, D. A., Wendler, D. S., & Greenbaum, C. J. (2015). Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. Diabetes care, 38(10), 1975-1985. https://doi.org/10.2337/dc15-1429

Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes : A Consensus Report. / Wherrett, Diane K.; Chiang, Jane L.; Delamater, Alan M.; Dimeglio, Linda A.; Gitelman, Stephen E.; Gottlieb, Peter A.; Herold, Kevan C.; Lovell, Daniel J.; Orchard, Trevor J.; Ryan, Christopher M.; Schatz, Desmond A.; Wendler, David S.; Greenbaum, Carla J.

In: Diabetes care, Vol. 38, No. 10, 10.2015, p. 1975-1985.

Research output: Contribution to journal › Article

Wherrett, DK, Chiang, JL, Delamater, AM, Dimeglio, LA, Gitelman, SE, Gottlieb, PA, Herold, KC, Lovell, DJ, Orchard, TJ, Ryan, CM, Schatz, DA, Wendler, DS & Greenbaum, CJ 2015, 'Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report', Diabetes care, vol. 38, no. 10, pp. 1975-1985. https://doi.org/10.2337/dc15-1429

Wherrett, Diane K. ; Chiang, Jane L. ; Delamater, Alan M. ; Dimeglio, Linda A. ; Gitelman, Stephen E. ; Gottlieb, Peter A. ; Herold, Kevan C. ; Lovell, Daniel J. ; Orchard, Trevor J. ; Ryan, Christopher M. ; Schatz, Desmond A. ; Wendler, David S. ; Greenbaum, Carla J. / Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes : A Consensus Report. In: Diabetes care. 2015 ; Vol. 38, No. 10. pp. 1975-1985.

@article{e46318b8d01a42dbac2bb07e209efb8e,

title = "Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report",

abstract = "Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.",

author = "Wherrett, {Diane K.} and Chiang, {Jane L.} and Delamater, {Alan M.} and Dimeglio, {Linda A.} and Gitelman, {Stephen E.} and Gottlieb, {Peter A.} and Herold, {Kevan C.} and Lovell, {Daniel J.} and Orchard, {Trevor J.} and Ryan, {Christopher M.} and Schatz, {Desmond A.} and Wendler, {David S.} and Greenbaum, {Carla J.}",

year = "2015",

month = oct,

doi = "10.2337/dc15-1429",

language = "English (US)",

volume = "38",

pages = "1975--1985",

journal = "Diabetes Care",

issn = "1935-5548",

publisher = "American Diabetes Association Inc.",

number = "10",

}

TY - JOUR

T1 - Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes

T2 - A Consensus Report

AU - Wherrett, Diane K.

AU - Chiang, Jane L.

AU - Delamater, Alan M.

AU - Dimeglio, Linda A.

AU - Gitelman, Stephen E.

AU - Gottlieb, Peter A.

AU - Herold, Kevan C.

AU - Lovell, Daniel J.

AU - Orchard, Trevor J.

AU - Ryan, Christopher M.

AU - Schatz, Desmond A.

AU - Wendler, David S.

AU - Greenbaum, Carla J.

PY - 2015/10

Y1 - 2015/10

N2 - Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.

AB - Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-modifying therapies may be different in the two populations. Understanding the developmental and regulatory pathways for type 1 diabetes-modifying therapies in children will enable industry, academia, funders, advocacy groups, and regulators to translate new science to clinical care. This consensus report characterizes the fundamental differences in type 1 diabetes between children and adults and proposes a thoughtful approach to better understand the development and regulatory pathways for type 1 diabetes therapies.

UR - http://www.scopus.com/inward/record.url?scp=84962406567&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962406567&partnerID=8YFLogxK

U2 - 10.2337/dc15-1429

DO - 10.2337/dc15-1429

M3 - Article

C2 - 26404927

AN - SCOPUS:84962406567

VL - 38

SP - 1975

EP - 1985

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 10

ER -